FY25 consensus $5.27. Narrows FY25 revenue view to $4.175B -$4.275B from $4.15B-$4.3B, consensus $4.22B.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- JAZZ Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Jazz Pharmaceuticals Appoints Dr. Ted Love to Board
- Jazz Pharmaceuticals Advances ONC201 Study for Glioma Treatment
- Jazz Pharmaceuticals’ ONC206 Study: A Potential Game-Changer in CNS Cancer Treatment
- Jazz Pharmaceuticals price target lowered to $199 from $204 at JPMorgan